Cellebrite DI (CLBT) Operating Expenses (2020 - 2025)

Cellebrite DI's Operating Expenses history runs 6 years deep, the most recent figure standing at $88.3 million for Q4 2025.

• On a quarterly basis, Operating Expenses rose 16.68% year-over-year to $88.3 million in Q4 2025; TTM through Dec 2025 was $334.0 million, a 18.57% increase from a year earlier, with the FY2025 full-year figure at $334.0 million, up 18.57% from the prior year.
• Operating Expenses advanced to $88.3 million in Q4 2025 per CLBT's latest filing, from $86.7 million in the prior quarter.
• Across five years, Operating Expenses topped out at $88.3 million in Q4 2025 and bottomed at $40.7 million in Q1 2021.
• The 5-year median for Operating Expenses is $58.9 million (2023), against an average of $63.2 million.
• Across the five-year window, Operating Expenses jumped 64.07% in 2021 and fell 0.69% in 2023, its largest moves.
• Year by year, Operating Expenses stood at $51.3 million in 2021, then increased by 1.85% to $52.2 million in 2022, then advanced by 20.85% to $63.1 million in 2023, then advanced by 19.97% to $75.7 million in 2024, then gained by 16.68% to $88.3 million in 2025.
• Per Business Quant, the three latest CLBT Operating Expenses figures stand at $88.3 million (Q4 2025), $86.7 million (Q3 2025), and $81.2 million (Q2 2025).